Business
ANI Pharmaceuticals develops and markets branded and generic medicines.
ANI Pharmaceuticals grew revenue, remained profitable, generated positive free cash flow at a 12.6% operating margin. Profit, margins and free cash flow improved with favorable principal statistical screens.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 43.8%OK
- Profitability — The company moved from a net loss of $18.522M to net income of $78.337MOK
- Cash flow — Free cash flow grew 258.7% to $171.39M from $47.781MOK
- Margins — Operating margin expanded 1248 bps to 12.58%OK
- Accounting — Profit, margins and free cash flow improved with favorable principal statistical screensNote
- Insiders — 0 purchases and 57 salesWatch
Where the revenue comes from
Fiscal 2025, as ANI PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Rare Disease and Brands total net revenues$484.0M
- Rare Disease total net revenues$422.6M
- Generics and Other total net revenues$399.4M
- Unapproved Products$24.1M
Leadership changes
From ANI PHARMACEUTICALS INC's own filings, the day they're filed.
- Matt Leonard · Chief Pharmacy Strategy Officer of Capsule · appointmenteff. 2023-08-21
- Thomas J. Haughey · Chairman · departure
Latest filings
- 8-K · Company announcement2026-08-24
- 8-K · Company announcement2026-08-07
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-05-21
- 8-K · Company announcement2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ANI PHARMACEUTICALS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.